

Do TZDs increase the risk of heart failure for patients with diabetes?

Serena Baskin, MD, Jon O. Neher, MD

Valley Family Medicine Residency Program, Renton, Wash

Sherry Dodson, MLS

University of Washington Health Sciences Library, Seattle

EVIDENCE-BASED ANSWER

Patients with diabetes who take thiazolidinediones (TZDs) have a higher incidence of congestive heart failure (CHF) than those who do not; the incidence of CHF is similar with the use of pioglitazone (Actos), troglitazone (Rezulin), or rosiglitazone (Avandia) (strength of recommendation [SOR]: **B**, based on a large retrospective cohort study). However, patients on regimens that include

pioglitazone but not insulin have lower rates of CHF than those taking insulin but not pioglitazone (SOR: **B**, based on a retrospective cohort study). Still, patients starting any TZD should be warned of the possibility of CHF and should be monitored for its development. TZDs are contraindicated for patients with class III and IV CHF (SOR: **C**, based on expert opinion).

CLINICAL COMMENTARY

Consider stopping TZDs for patients developing edema or CHF

Improved glycemic control decreases the risk of end organ damage and heart failure in patients with diabetes. Thiazolidinediones are very useful drugs, particularly for patients with marked insulin resistance and hyperlipidemia. However, they do precipitate edema and heart failure. The edema can be severe enough to lead to discontinuation

of the drug, and the risk of heart failure limits the population in which they can be used. They can be used safely in some cardiac patients but, as noted in the article, they should be avoided or used with caution in patients with CHF. Patients taking a TZD who subsequently develop edema should be carefully evaluated for CHF.

Richard Hoffman, MD
Chesterfield Family Practice,
Richmond, Va

■ Evidence summary

A retrospective cohort study of health insurance claims compared the incidence of CHF among 5441 patients with diabetes who had taken TZDs (rosiglitazone, troglitazone, or pioglitazone) vs 28,103 who had not. Patients were allowed other oral agents and insulin, and they were followed for up to 6 years. The TZD group had more patients on insulin and with pre-existing comorbidities. Based on Kaplan-Meier estimates, which control for censored information, the incidence of new heart failure at 40 months was 8.2% in the TZD group and 5.3% in the non-TZD group (number needed to harm [NNH]=34.5). Using a multivariate analysis that controlled for the coadministration of insulin, the hazard

ratio for TZD use was 1.76 (95% confidence interval [CI], 1.43–2.17).¹ The incidence of CHF was 3.24% in the troglitazone group (n=1665), 2.39% in the rosiglitazone group (n=1882), and 1.63% in the pioglitazone group (n=1347). The difference in these rates is not statistically significant. Of the 28,103 patients not on a TZD, 1.41% developed heart failure. Individual agents were not compared with placebo.

A manufacturer-sponsored study that combined data from 4 separate unpublished randomized controlled trials compared the incidence of CHF at 1 year for patients treated with pioglitazone (as monotherapy and in combination with other oral agents) with those treated only with other oral agents.

Cardiac failure was noted in 12 of 1857 in the pioglitazone group vs 10 of 1856 subjects in the non-pioglitazone groups (not statistically significant). The paper did not comment on how the patients were recruited, how outcomes were measured, or why the 4 original studies were not published.²

Another manufacturer-sponsored retrospective cohort study of pioglitazone analyzed insurance claims data to compare the incidence of CHF among 1668 adult patients taking pioglitazone (and possibly other medications, but not insulin) vs 1668 adult patients taking insulin (and possibly other medications, but not a TZD). The 2 groups were matched in terms of comorbid conditions, but statistical analysis did not take disease severity into account. The incidence of CHF was 2% of pioglitazone users compared with 4% of patients using insulin (NNH for insulin=50). In addition, CHF-related hospitalizations were 0.7% for CHF in the pioglitazone group vs 2.5% in the insulin group (NNH for insulin=55). Both of these findings are statistically significant.³

Recommendations from others

The American Diabetes Association/American Heart Association recommends that patients be evaluated for heart disease or heart failure before starting TZD therapy and monitored for symptoms thereafter. Patients who are at risk for developing CHF, who already have New York Heart Association class I or II CHF, or who take insulin should begin TZD therapy with low doses that are titrated up gradually. The US Food and Drug Administration has not approved TZDs for patients with class III or IV CHF, as there are no studies in these populations.⁴

REFERENCES

1. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. *Diabetes Care* 2003; 26:2983-2989.
2. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. *Int J Clin Pract* 2004; 58:833-837.

3. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. *Clin Ther* 2004; 26:1400-1410.
4. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, October 7, 2003. *Circulation* 2003; 108:2941-2948.

What are Clinical Inquiries?

Clinical Inquiries answer recent questions from the practices of family physicians. Practicing family physicians choose the most relevant questions submitted through a web-based voting system operated by the Family Physicians Inquiries Network (FPIN; online at www.fpin.org).

FPIN is national, not-for-profit consortium of family medicine departments, community residency programs, academic health sciences libraries, primary care practice-based research networks, and other specialists. Once questions are selected, FPIN editors then organize teams of clinicians and librarians to answer them based on systematic review of the world literature. Answers are developed through an explicit, systematic method:

- FPIN librarians and editors identify questions recently answered in best evidence sources (e.g. Cochrane Reviews, Clinical Evidence, the US Preventive Services Task Force, Evidence Based Guidelines, a published systematic review).
- FPIN librarians then conduct systematic and standardized literature searches of best evidence sources, Medline, and other databases in collaboration with an FPIN clinician or clinicians. If a best evidence source has been identified, the search begins from the date of the search conducted for that source. Otherwise, the searches are comprehensive.
- FPIN clinician authors then choose the highest quality original research sources, and critically appraise the research and integrate the findings in the Evidence Based Answer and Evidence Summary section of Clinical Inquiries. Authoritative sources are also quoted in the "Recommendations from Others" section of the Clinical Inquiry.
- Each Clinical Inquiry is reviewed by 4 or more peers or editors before publication in *JFP*.
- FPIN medical librarians are accountable for the thoroughness of the literature search, for recording the databases searched, search hedges used and the search terms. The details of each search is available to any interested reader (contact managingeditor@fpin.org).
- Finally, a practicing family physician or other clinician writes an accompanying commentary to provide a clinical perspective.

FAST TRACK

TZDs are useful for patients with marked insulin resistance, but they do precipitate edema and heart failure